MedCity News’ Brandon Glenn breaks down the recent FDA approval of Meridian Bioscience’s pediatric version of its C. difficile test on this week’s edition of Health Journal on ONN.
Meridian said its new product is the only C. difficile test that the U.S. Food and Drug Administration has cleared for use on children under the age of 2, according to a statement from the Cincinnati-area company.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
An earlier version of the test, which the company calls the “illumigene,” was cleared for commercialization by the FDA in July. However, that clearance didn’t apply to children.
The test provides results within an hour and requires about two minutes of hands-on time per sample.
ONN broadcasts Health Journal featuring MedCity News throughout the week starting on Tuesdays.
Related articles
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
- Meridian Bioscience gets FDA OK on pediatric C. difficile test (medcitynews.com)
